X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (417) 417
3-hydroxysteroid dehydrogenases - antagonists & inhibitors (391) 391
3-hydroxysteroid dehydrogenases - metabolism (276) 276
female (258) 258
male (247) 247
humans (233) 233
rats (199) 199
index medicus (151) 151
endocrinology & metabolism (122) 122
3-hydroxysteroid dehydrogenases - genetics (118) 118
kinetics (101) 101
dihydrotestosterone - analogs & derivatives (96) 96
enzyme inhibitors - pharmacology (96) 96
biochemistry & molecular biology (90) 90
dihydrotestosterone - pharmacology (79) 79
pregnancy (76) 76
3-alpha-hydroxysteroid dehydrogenase (74) 74
cells, cultured (73) 73
aldo-keto reductase family 1 member c3 (71) 71
expression (66) 66
progesterone - biosynthesis (60) 60
steroidogenesis (60) 60
dose-response relationship, drug (59) 59
mice (59) 59
hydroxyprostaglandin dehydrogenases - antagonists & inhibitors (55) 55
in vitro techniques (54) 54
rats, inbred strains (51) 51
testosterone (51) 51
hydroxyprostaglandin dehydrogenases - metabolism (48) 48
rats, sprague-dawley (47) 47
pharmacology & pharmacy (44) 44
chorionic gonadotropin - pharmacology (43) 43
progesterone - metabolism (42) 42
substrate specificity (42) 42
progesterone - blood (41) 41
reproductive biology (41) 41
testis - drug effects (41) 41
liver - enzymology (39) 39
structure-activity relationship (38) 38
toxicology (38) 38
rna, messenger - metabolism (37) 37
leydig cells - drug effects (36) 36
pregnenolone - metabolism (36) 36
17-hydroxysteroid dehydrogenases - metabolism (35) 35
cell line, tumor (35) 35
gene-expression (35) 35
progesterone (35) 35
testis - enzymology (35) 35
endocrine system (34) 34
leydig cells - metabolism (34) 34
testosterone - metabolism (33) 33
17-hydroxysteroid dehydrogenases - antagonists & inhibitors (32) 32
3-hydroxysteroid dehydrogenases - chemistry (32) 32
testosterone - biosynthesis (32) 32
adult (31) 31
article (31) 31
microsomes - enzymology (31) 31
testis - metabolism (31) 31
time factors (31) 31
3-hydroxysteroid dehydrogenases - biosynthesis (29) 29
enzyme inhibitors - chemistry (29) 29
inhibition (29) 29
testosterone - blood (29) 29
cholesterol side-chain cleavage enzyme - genetics (27) 27
enzymes (27) 27
granulosa cells - metabolism (27) 27
hydroxyprostaglandin dehydrogenases - genetics (27) 27
physiological aspects (27) 27
binding sites (26) 26
progesterone - pharmacology (26) 26
rats, wistar (26) 26
3-beta-hydroxysteroid dehydrogenase (25) 25
chemistry, medicinal (25) 25
indomethacin - pharmacology (25) 25
luteinizing-hormone (25) 25
metabolism (25) 25
models, molecular (25) 25
steroids - biosynthesis (25) 25
adrenal glands - enzymology (24) 24
androstenols - pharmacology (24) 24
ovary - drug effects (24) 24
granulosa cells - drug effects (23) 23
hydrocortisone - blood (23) 23
molecular structure (23) 23
oxidation-reduction (23) 23
steroid 17-alpha-hydroxylase - metabolism (23) 23
adrenal glands - drug effects (22) 22
dihydrotestosterone - metabolism (22) 22
hormones, hormone substitutes, and hormone antagonists (22) 22
receptor (22) 22
rna, messenger - genetics (22) 22
steroid 17-alpha-hydroxylase - antagonists & inhibitors (22) 22
swine (22) 22
trilostane (22) 22
cell biology (21) 21
cell line (21) 21
corpus luteum - drug effects (21) 21
cytosol - enzymology (21) 21
dihydrotestosterone - therapeutic use (21) 21
estradiol - blood (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2012, Volume 55, Issue 5, pp. 2311 - 2323
Aldo-keto reductase 1C3 (AKR1C3; type 5 17 beta-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated... 
TARGET | CHEMISTRY, MEDICINAL | ISOFORMS | PURIFICATION | BIOLOGICAL EVALUATION | ABIRATERONE ACETATE | 17-BETA-HSD1 | RESISTANT PROSTATE-CANCER | EXPRESSION | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | NONSTEROIDAL INHIBITORS | Antineoplastic Agents - chemical synthesis | Humans | Male | Structure-Activity Relationship | Hydroxyprostaglandin Dehydrogenases - metabolism | Fenamates - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | 20-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | 3-Hydroxysteroid Dehydrogenases - metabolism | Antineoplastic Agents - pharmacology | Prostatic Neoplasms - drug therapy | Fenamates - chemistry | Testosterone - biosynthesis | Cyclooxygenase Inhibitors - chemistry | Antineoplastic Agents - chemistry | Hydroxyprostaglandin Dehydrogenases - genetics | Cyclooxygenase Inhibitors - pharmacology | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Aldo-Keto Reductase Family 1 Member C3 | Testosterone - antagonists & inhibitors | Cyclooxygenase 2 - metabolism | Cyclooxygenase Inhibitors - chemical synthesis | Cell Line, Tumor | Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Fenamates - chemical synthesis | Cyclooxygenase 1 - metabolism | 3-Hydroxysteroid Dehydrogenases - genetics | Isoenzymes - antagonists & inhibitors | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 07/2015, Volume 523, Issue 7560, pp. 347 - 351
Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5... 
ANDROGEN RECEPTOR | 3-BETA-HYDROXYSTEROID DEHYDROGENASE | CYP17A1 INHIBITION | MECHANISM | TESTOSTERONE | RATIONALE | MULTIDISCIPLINARY SCIENCES | INCREASED SURVIVAL | CHEMOTHERAPY | EXPOSURE | ENZALUTAMIDE | Chromatin - metabolism | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Androgens - biosynthesis | Male | Androstenes - pharmacology | Androgen Receptor Antagonists - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Biotransformation | Cell Division | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - metabolism | 3-Hydroxysteroid Dehydrogenases - metabolism | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Phenylthiohydantoin - pharmacology | Prostatic Neoplasms - pathology | Androstenes - therapeutic use | 5-alpha Reductase Inhibitors - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Phenylthiohydantoin - analogs & derivatives | Androgen Receptor Antagonists - metabolism | Xenograft Model Antitumor Assays | Androstenes - chemistry | Animals | Biosynthetic Pathways - drug effects | Survival Analysis | 5-alpha Reductase Inhibitors - pharmacology | Androstenes - metabolism | Prostatic Neoplasms - enzymology | Mice | Steroid 17-alpha-Hydroxylase - metabolism | 5-alpha Reductase Inhibitors - metabolism | Androgens - metabolism | Enzymes | Testosterone | Androgens | Metabolites | Ligands | Gene expression | Prostate cancer | Tumors
Journal Article
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 03/2011, Volume 39, Issue 3, pp. 510 - 521
Boceprevir (SCH 503034), a protease inhibitor, is under clinical development for the treatment of human hepatitis C virus infections. In human liver... 
METABOLISM | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NS3 PROTEASE | ALDO-KETO REDUCTASES | CARBONYL REDUCTION | NEUROSTEROIDS | SUPERFAMILY | PHARMACOLOGY & PHARMACY | AGENTS | DEHYDROGENASE | HIV-INTEGRASE INHIBITOR | Liver - enzymology | Proline - metabolism | Stereoisomerism | Humans | Drugs, Investigational - metabolism | Hydroxyprostaglandin Dehydrogenases - metabolism | Urea - chemistry | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Drugs, Investigational - chemistry | Serine Proteinase Inhibitors - chemistry | Cytochrome P-450 CYP3A - genetics | Urea - analogs & derivatives | 3-Hydroxysteroid Dehydrogenases - metabolism | Hydroxysteroid Dehydrogenases - metabolism | Urea - metabolism | Molecular Structure | Oligopeptides - chemistry | Recombinant Proteins - metabolism | Oxidation-Reduction | Proline - analogs & derivatives | Subcellular Fractions - drug effects | Enzyme Inhibitors - pharmacology | Serine Proteinase Inhibitors - metabolism | Hydroxysteroid Dehydrogenases - genetics | Oligopeptides - metabolism | Subcellular Fractions - metabolism | Hydroxyprostaglandin Dehydrogenases - genetics | Proline - chemistry | Hepacivirus - enzymology | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Cytochrome P-450 CYP3A Inhibitors | Aldo-Keto Reductase Family 1 Member C3 | Cytochrome P-450 CYP3A - metabolism | Biotransformation - drug effects | Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Kinetics | 3-Hydroxysteroid Dehydrogenases - genetics | Viral Nonstructural Proteins - antagonists & inhibitors | Subcellular Fractions - enzymology
Journal Article
Oncology Reports, ISSN 1021-335X, 03/2017, Volume 37, Issue 4, pp. 2025 - 2032
Resistance to anticancer medications often leads to poor outcomes. The present study explored an effective approach for enhancing chemotherapy targeted against... 
aldo-keto reductase | cisplatin | mefenamic acid | 5-FU | Cisplatin, 5-FU | Mefenamic acid | Aldo-keto reductase | HUMAN OVARIAN | AKR1C3 | CISPLATIN RESISTANCE | TUMOR-CELLS | CHEMOTHERAPY | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | LUNG-CANCER | CARCINOMA CELL-LINE | ONCOLOGY | SUPERFAMILY | EXPRESSION | 20-Hydroxysteroid Dehydrogenases - biosynthesis | 3-Hydroxysteroid Dehydrogenases - biosynthesis | 20-Hydroxysteroid Dehydrogenases - genetics | Humans | Hydroxyprostaglandin Dehydrogenases - biosynthesis | Hydroxysteroid Dehydrogenases - genetics | Hydroxyprostaglandin Dehydrogenases - genetics | Cisplatin - administration & dosage | Neoplasms - drug therapy | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Fluorouracil - administration & dosage | 20-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Neoplasms - genetics | Aldo-Keto Reductase Family 1 Member C3 | Mefenamic Acid - administration & dosage | Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Hydroxysteroid Dehydrogenases - biosynthesis | Gene Expression Regulation, Neoplastic - drug effects | HeLa Cells | Oxidoreductases | 3-Hydroxysteroid Dehydrogenases - genetics | Neoplasms - pathology | Drug Resistance, Neoplasm - drug effects | Care and treatment | Patient outcomes | Genetic aspects | Drug resistance | Gene expression | Health aspects | Methods | Cancer | Studies | Enzymes | Oxidative stress | Chemotherapy | Genes | Rodents | Prostate | Experiments | Cancer therapies | Deoxyribonucleic acid--DNA | Apoptosis
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 01/2017, Volume 16, Issue 1, pp. 35 - 44
Abiraterone suppresses intracrine androgen synthesis via inhibition of CYP17A1. However, clinical evidence suggests that androgen synthesis is not fully... 
STEROIDOGENIC ENZYME AKR1C3 | CYP17A1 INHIBITION | ONCOLOGY | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | 17-BETA-HYDROXYSTEROID-DEHYDROGENASE AKR1C3 | INCREASED SURVIVAL | ENZALUTAMIDE RESISTANCE | ANTITUMOR-ACTIVITY | ANDROGEN RECEPTOR GENE | EXPRESSION | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | Prostatic Neoplasms - metabolism | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Male | Androstenes - pharmacology | Hydroxyprostaglandin Dehydrogenases - metabolism | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Prostatic Neoplasms - genetics | Cell Transformation, Neoplastic - genetics | 3-Hydroxysteroid Dehydrogenases - metabolism | Transcription, Genetic | Prostatic Neoplasms - drug therapy | Disease Models, Animal | Prostatic Neoplasms - pathology | Gene Expression | Antineoplastic Agents, Hormonal - pharmacology | Cell Transformation, Neoplastic - metabolism | Hydroxyprostaglandin Dehydrogenases - genetics | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Animals | Aldo-Keto Reductase Family 1 Member C3 | Cell Line, Tumor | Mice | Cell Transformation, Neoplastic - drug effects | 3-Hydroxysteroid Dehydrogenases - genetics | Neoplasm Staging | Medical research | Transcription | Medical services | Clinical trials | Activation | Signaling | Androgens | Synthesis | Steroidogenesis | Indomethacin | Inhibition | Prostate cancer | Prostate | Cancer | AKR1C3 | prostate cancer | intracrine androgens | abiraterone | indomethacin
Journal Article
Journal Article
Journal Article
Journal of Steroid Biochemistry and Molecular Biology, ISSN 0960-0760, 2011, Volume 125, Issue 1, pp. 95 - 104
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2013, Volume 19, Issue 20, pp. 5613 - 5625
Journal Article
Journal of Steroid Biochemistry and Molecular Biology, ISSN 0960-0760, 07/2017, Volume 171, pp. 270 - 280
17beta-hydroxysteroid dehydrogenase type 5 (17β-HSD5) is an important enzyme associated with sex steroid metabolism in hormone-dependent cancer. However,... 
GRP78 | PGK1 | 17β-HSD5 | Cell viability | Breast cancer cell proteome | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | C-MYC | 17 beta-HSD5 | 17-BETA-HYDROXYSTEROID-DEHYDROGENASE | KETO REDUCTASE SUPERFAMILY | ENDOCRINOLOGY & METABOLISM | RESISTANCE | MYC ONCOGENE EXPRESSION | PROGNOSTIC MARKER | PHOSPHOGLYCERATE KINASE | CARCINOMA | PROTEOMICS | Receptors, Estrogen - metabolism | Cell Proliferation | Humans | Two-Dimensional Difference Gel Electrophoresis | Gene Expression Regulation, Neoplastic | Heat-Shock Proteins - antagonists & inhibitors | Neoplasm Proteins - antagonists & inhibitors | Gene Expression Profiling | Neoplasm Proteins - metabolism | Hydroxyprostaglandin Dehydrogenases - metabolism | NM23 Nucleoside Diphosphate Kinases - genetics | NM23 Nucleoside Diphosphate Kinases - metabolism | Breast Neoplasms - metabolism | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Heat-Shock Proteins - genetics | Phosphoglycerate Kinase - chemistry | MCF-7 Cells | RNA Interference | 3-Hydroxysteroid Dehydrogenases - metabolism | Female | Proteomics - methods | Hydroxyprostaglandin Dehydrogenases - chemistry | Neoplasm Proteins - genetics | Phosphoglycerate Kinase - genetics | NM23 Nucleoside Diphosphate Kinases - chemistry | Cell Survival | Heat-Shock Proteins - metabolism | Neoplasm Proteins - chemistry | Proto-Oncogene Proteins c-myc - metabolism | Hydroxyprostaglandin Dehydrogenases - genetics | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Image Processing, Computer-Assisted | Aldo-Keto Reductase Family 1 Member C3 | Breast Neoplasms - pathology | 3-Hydroxysteroid Dehydrogenases - chemistry | Proto-Oncogene Proteins c-myc - genetics | Enzyme Activation | 3-Hydroxysteroid Dehydrogenases - genetics | Proto-Oncogene Proteins c-myc - chemistry | Heat-Shock Proteins - chemistry | Phosphoglycerate Kinase - metabolism | Ubiquitin | Care and treatment | Breast cancer | Cancer | Apoptosis | Analysis | Physiological aspects | Development and progression | Cellular signal transduction | Metastasis | Gene expression | Estradiol | Mass spectrometry
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 08/2014, Volume 278, Issue 3, pp. 238 - 248
Pharmacokinetic drug resistance is a serious obstacle that emerges during cancer chemotherapy. In this study, we investigated the possible role of aldo-keto... 
Anthracyclines | Aldo-keto reductase 1C3 | Drug resistance | Metabolism | Enzyme induction | DOXORUBICIN | TUMOR-CELLS | INDUCTION | STEROID-HORMONE | DAUNORUBICIN | ENDOMETRIAL CANCER | BREAST-CANCER | 5 17-BETA-HYDROXYSTEROID-DEHYDROGENASE AKR1C3 | PROSTATE-CANCER | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MCF-7 CELLS | Antibiotics, Antineoplastic - pharmacology | Humans | Daunorubicin - agonists | Daunorubicin - pharmacology | Idarubicin - pharmacology | Neoplasm Proteins - antagonists & inhibitors | Neoplasm Proteins - metabolism | Anthracyclines - agonists | Hydroxyprostaglandin Dehydrogenases - metabolism | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Anthracyclines - pharmacology | Biotransformation | Anthracyclines - metabolism | Enzyme Induction - drug effects | 3-Hydroxysteroid Dehydrogenases - metabolism | Doxorubicin - metabolism | Daunorubicin - metabolism | Neoplasm Proteins - genetics | Antibiotics, Antineoplastic - agonists | Carcinoma - drug therapy | Idarubicin - metabolism | Recombinant Proteins - metabolism | Cell Survival - drug effects | Oxidation-Reduction | Flavanones - pharmacology | Enzyme Inhibitors - pharmacology | Recombinant Proteins - chemistry | Hydroxyprostaglandin Dehydrogenases - genetics | Drug Synergism | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Aldo-Keto Reductase Family 1 Member C3 | Cell Line, Tumor | Kinetics | 3-Hydroxysteroid Dehydrogenases - genetics | Antibiotics, Antineoplastic - metabolism | Idarubicin - agonists | Doxorubicin - pharmacology | Drug Resistance, Neoplasm - drug effects | Physiological aspects | Chemotherapy | Cancer cells | Cancer | Index Medicus | CARBONYLS | METABOLISM | NEOPLASMS | ENZYMES | DRUGS | TOXICITY | INCUBATION | 60 APPLIED LIFE SCIENCES | ENZYME INDUCTION | CHEMOTHERAPY
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 08/2015, Volume 290, Issue 34, pp. 20865 - 20879
Re-activation of androgen receptor (AR) activity is the main driver for development of castration-resistant prostate cancer. We previously reported that the... 
TARGET | ANDROGEN RECEPTOR | ABSENTIA HOMOLOG 2 | IN-VITRO | BIOCHEMISTRY & MOLECULAR BIOLOGY | RESISTANCE | INHIBITORS | HYPOXIA | EXPRESSION | TUMORIGENESIS | ABIRATERONE | Neoplasm Transplantation | RNA, Small Interfering - genetics | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Ubiquitin-Protein Ligases - antagonists & inhibitors | Male | Hydroxyprostaglandin Dehydrogenases - metabolism | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Prostate - pathology | Ubiquitination | Prostatic Neoplasms - genetics | Proteolysis | 3-Hydroxysteroid Dehydrogenases - metabolism | Prostate-Specific Antigen - metabolism | Nuclear Proteins - genetics | Prostate-Specific Antigen - genetics | Prostatic Neoplasms - pathology | Signal Transduction | Enzyme Stability | Ubiquitin-Protein Ligases - metabolism | Nuclear Proteins - metabolism | Hydroxyprostaglandin Dehydrogenases - genetics | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Animals | Receptors, Androgen - genetics | Aldo-Keto Reductase Family 1 Member C3 | Mice, Nude | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Prostatic Neoplasms - enzymology | Protein Binding | Mice | Prostate - enzymology | Proteasome Endopeptidase Complex - metabolism | 3-Hydroxysteroid Dehydrogenases - genetics | Androgens - metabolism | Ubiquitin-Protein Ligases - genetics | RNA, Small Interfering - metabolism | ubiquitin ligase | transcription regulation | androgen | prostate cancer | androgen receptor | Cell Biology
Journal Article
Toxicological Sciences, ISSN 1096-6080, 2011, Volume 119, Issue 1, pp. 209 - 217
Journal Article